FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:377-384 August 8, 1996 Number 6 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Bacteremia with the Mycobacterium avium complex is common in patients with the acquired immunodeficiency syndrome (AIDS), but the most effective treatment for this infection remains unclear.

Methods We randomly assigned 229 patients with AIDS and M. avium complex bacteremia to receive either rifampin (600 mg daily), ethambutol (approximately 15 mg per kilogram of body weight daily), clofazimine (100 mg daily), and ciprofloxacin (750 mg twice daily) (the four-drug group) or rifabutin (600 mg daily), ethambutol (as above), and clarithromycin (1000 mg twice daily) (the three-drug group). In the three-drug group the dose of rifabutin was reduced by half after 125 patients were randomized, because 24 of 63 patients had uveitis.

Results Among 187 patients who could be evaluated, blood cultures became negative more often in the three-drug group than in the four-drug group (69 percent vs. 29 percent, P<0.001). Among patients treated for at least four weeks, the bacteremia resolved more frequently in the three-drug group (78 percent vs. 40 percent, P<0.001). In the three-drug group, bacteremia resolved more often with the 600-mg dose of rifabutin than with the 300-mg dose (P = 0.025), but the latter regimen was more effective than the four-drug regimen (P<0.05). The median survival was 8.6 months in the three-drug group and 5.2 months in the four-drug group (P = 0.001). The median Karnofsky performance score was higher in the three-drug group than in the four-drug group from week 2 to week 16 (P<0.05). Mild uveitis developed in 3 of the 53 patients receiving the 300-mg dose of rifabutin, an incidence about one quarter that observed with the 600-mg dose (P<0.001).

Conclusions In patients with AIDS and M. avium complex bacteremia, treatment with the three-drug regimen of rifabutin, ethambutol, and clarithromycin leads to resolution of the bacteremia more frequently and more rapidly than treatment with rifampin, ethambutol, clofazimine, and ciprofloxacin, and survival rates are better.

Source Information

From the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton (S.D.S.); the National Centre, Canadian HIV Trials Network, Vancouver, B.C. (J.S., D.P.Z.); the Division of Infectious Diseases, St. Paul's Hospital and University of British Columbia, Vancouver (P.P.); the Division of Infectious Diseases, Toronto Hospital and University of Toronto, Toronto (I.S., S.L.W.); the Division of Infectious Diseases, St. Michael's Hospital and University of Toronto, Toronto (I.W.F.); the Division of Infectious Diseases, University of Calgary, Calgary, Alta. (M.J.G.); the Division of Infectious Diseases, Sunnybrook Health Science Centre and University of Toronto, Toronto (A.R.R.); the Division of Infectious Diseases, Montreal Chest Institute and McGill University, Montreal (R.G.L.); the Division of Infectious Diseases, Wellesley Hospital and University of Toronto, Toronto (M.M.F.); and the Division of Immunology, Montreal General Hospital and McGill University, Montreal (C.M.T.).

Address reprint requests to Dr. Shafran at the Division of Infectious Diseases, Department of Medicine, University of Alberta, 2E4.11 Walter C. Mackenzie Health Sciences Centre, 8440–112 St., Edmonton, AB T6G 2B7, Canada.

Full Text of this Article

This article has been cited by other articles:

• Jenkins, P A, Campbell, I A, Banks, J, Gelder, C M, Prescott, R J, Smith, A P (2008). Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 63: 627-634 [Abstract] [Full Text]  
• Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., Iseman, M., Olivier, K., Ruoss, S., von Reyn, C. F., Wallace, R. J. Jr., Winthrop, K., on behalf of the ATS Mycobacterial Diseases Subcom, (2007). An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am. J. Respir. Crit. Care Med. 175: 367-416 [Full Text]  
• Schonfeld, N. (2006). The mycobacterial mystery. Eur Respir J 28: 1076-1078 [Full Text]  
• Field, S. K., Cowie, R. L. (2006). Lung Disease Due to the More Common Nontuberculous Mycobacteria. Chest 129: 1653-1672 [Abstract] [Full Text]  
• Griffith, D. E., Brown-Elliott, B. A., Shepherd, S., McLarty, J., Griffith, L., Wallace, R. J. Jr. (2005). Ethambutol Ocular Toxicity in Treatment Regimens for Mycobacterium avium Complex Lung Disease. Am. J. Respir. Crit. Care Med. 172: 250-253 [Abstract] [Full Text]  
• Bakker-Woudenberg, I. A. J. M., van Vianen, W., van Soolingen, D., Verbrugh, H. A., van Agtmael, M. A. (2005). Antimycobacterial Agents Differ with Respect to Their Bacteriostatic versus Bactericidal Activities in Relation to Time of Exposure, Mycobacterial Growth Phase, and Their Use in Combination. Antimicrob. Agents Chemother. 49: 2387-2398 [Abstract] [Full Text]  
• Field, S. K., Fisher, D., Cowie, R. L. (2004). Mycobacterium avium complex Pulmonary Disease in Patients Without HIV Infection. Chest 126: 566-581 [Abstract] [Full Text]  
• Maslow, J. N., Irani, V. R., Lee, S.-H., Eckstein, T. M., Inamine, J. M., Belisle, J. T. (2003). Biosynthetic specificity of the rhamnosyltransferase gene of Mycobacterium avium serovar 2 as determined by allelic exchange mutagenesis. Microbiology 149: 3193-3202 [Abstract] [Full Text]  
• (2003). American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis. Am. J. Respir. Crit. Care Med. 167: 603-662 [Full Text]  
• Kunimoto, D. Y., Peppler, M. S., Talbot, J., Phillips, P., Shafran, S. D. (2003). Analysis of Mycobacterium avium Complex Isolates from Blood Samples of AIDS Patients by Pulsed-Field Gel Electrophoresis. J. Clin. Microbiol. 41: 498-499 [Abstract] [Full Text]  
• Zaidi, S. A., Cervia, J. S. (2002). Diagnosis and Management of Infectious Esophagitis Associated with Human Immunodeficiency Virus Infection. J Int Assoc Physicians AIDS Care (Chic Ill) 1: 53-62 [Abstract]  
• Silva, R. A., Pais, T. F., Appelberg, R. (2001). Blocking the Receptor for IL-10 Improves Antimycobacterial Chemotherapy and Vaccination. J. Immunol. 167: 1535-1541 [Abstract] [Full Text]  
• Research Committee of the British Thoracic Society, (2001). First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 56: 167-172 [Abstract] [Full Text]  
• Purdy, B. D. (2000). Management and Prevention of Opportunistic Infections in the HIV-Infected Patient. Journal of Pharmacy Practice 13: 475-498 [Abstract]  
• Cynamon, M. H., Carter, J. L., Shoen, C. M. (2000). Activity of ABT-773 against Mycobacterium avium Complex in the Beige Mouse Model. Antimicrob. Agents Chemother. 44: 2895-2896 [Abstract] [Full Text]  
• Jordan, M. K., Polis, M. A., Kelly, G., Narang, P. K., Masur, H., Piscitelli, S. C. (2000). Effects of Fluconazole and Clarithromycin on Rifabutin and 25-O-Desacetylrifabutin Pharmacokinetics. Antimicrob. Agents Chemother. 44: 2170-2172 [Abstract] [Full Text]  
• Kovacs, J. A., Masur, H. (2000). Prophylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection. NEJM 342: 1416-1429 [Full Text]  
• Wang, L., Slayden, R. A., Barry, C. E. III, Liu, J. (2000). Cell Wall Structure of a Mutant of Mycobacterium smegmatis Defective in the Biosynthesis of Mycolic Acids. J. Biol. Chem. 275: 7224-7229 [Abstract] [Full Text]  
• Peters, K., Leitzke, S., Diederichs, J. E., Borner, K., Hahn, H., Muller, R. H., Ehlers, S. (2000). Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother 45: 77-83 [Abstract] [Full Text]  
• Koletar, S. L., Berry, A. J., Cynamon, M. H., Jacobson, J., Currier, J. S., MacGregor, R. R., Dunne, M. W., Williams, D. J. (1999). Azithromycin as Treatment for Disseminated Mycobacterium avium Complex in AIDS Patients. Antimicrob. Agents Chemother. 43: 2869-2872 [Abstract] [Full Text]  
• Jagannath, C., Emanuele, M. R., Hunter, R. L. (1999). Activities of Poloxamer CRL-1072 against Mycobacterium avium in Macrophage Culture and in Mice. Antimicrob. Agents Chemother. 43: 2898-2903 [Abstract] [Full Text]  
• Ambati, J., Wynne, K. B, Angerame, M. C, Robinson, M. R (1999). Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis. Br. J. Ophthalmol. 83: 1153-1158 [Abstract] [Full Text]  
• Roger, P.-M., Carles, M., Agussol-Foin, I., Pandiani, L., Keita-Perse, O., Mondain, V., De Salvador, F., Dellamonica, P. (1999). Efficacy and safety of an intravenous induction therapy for treatment of disseminated Mycobacterium avium complex infection in AIDS patients: a pilot study. J Antimicrob Chemother 44: 129-131 [Abstract] [Full Text]  
• CORBETT, E. L., CHURCHYARD, G. J., HAY, M., HERSELMAN, P., CLAYTON, T., WILLIAMS, B., HAYES, R., MULDER, D., DE COCK, K. M. (1999). The Impact of HIV Infection on Mycobacterium kansasii Disease in South African Gold Miners. Am. J. Respir. Crit. Care Med. 160: 10-14 [Abstract] [Full Text]  
• Grouhi, M., Wang, E., Reid, B., Roifman, C. M. (1999). Long-term Remission for Disseminated Mycobacterium avium-intracellulare Complex Associated With Antibody Deficiency. Pediatrics 103: e13-13 [Abstract] [Full Text]  
• Gatti, G., Papa, P., Torre, D., Andreoni, M., Poggio, A., Bassetti, M., Marone, P. (1998). Population Pharmacokinetics of Rifabutin in Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother. 42: 2017-2023 [Abstract] [Full Text]  
• Nelson, K. G., Griffith, D. E., Brown, B. A., Wallace, R. J. Jr (1998). Results of operation in Mycobacterium avium-intracellulare lung disease. Ann. Thorac. Surg. 66: 325-330 [Abstract] [Full Text]  
• Brun-Pascaud, M., Rajagopalan-Levasseur, P., Chau, F., Bertrand, G., Garry, L., Derouin, F., Girard, P.-M. (1998). Drug Evaluation of Concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium Complex Infections in a Rat Model. Antimicrob. Agents Chemother. 42: 1068-1072 [Abstract] [Full Text]  
• Piersimoni, C, Nista, D, Bornigia, S, De Sio, G (1998). Evaluation of a new method for rapid drug susceptibility testing of Mycobacterium avium complex isolates by using the mycobacteria growth indicator tube [In Process Citation]. J. Clin. Microbiol. 36: 64-67 [Abstract] [Full Text]  
• (1997). Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria. Am. J. Respir. Crit. Care Med. 156: 1-25 [Full Text]  
• Beiser, C. (1997). Recent advances: HIV infection–II. BMJ 314: 579-579 [Full Text]  
• (1996). MAC Treatment: Not Yet Out of the Woods. AIDS Clin Care 1996: 6-6 [Full Text]  
• (1996). PREVENTING AND TREATING DISSEMINATED MAC IN AIDS. JWatch General 1996: 4-4 [Full Text]  
• Horsburgh, C. R. (1996). Advances in the Prevention and Treatment of Mycobacterium avium Disease. NEJM 335: 428-430 [Full Text]